Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals presented new analyses at the European Society of Cardiology Congress in Munich supporting the use of Amvuttra across a range of transthyretin amyloidosis patients, including those already on Pfizer's tafamidis, and reported encouraging subgroup findings for its experimental hypertension drug zilebesiran. In the Phase 3 HELIOS-B study, 259 of the 654 treated patients were taking tafamidis at baseline, and Amvuttra's effect on the composite of death and recurrent cardiovascular events appeared consistent regardless of tafamidis use. Patients on Amvuttra also showed better preservation of walking ability and a 25% less deterioration in a composite measure of physical and mental function, with a 52% reduction in the risk of decline on that measure. A pooled analysis of 1,402 patients from four Phase 3 studies of Amvuttra and Onpattro showed consistent effects in women and men across cardiac and neurological forms of the disease. For zilebesiran, a post hoc subgroup analysis from the Phase 2 KARDIA-3 study showed larger systolic blood pressure reductions in high-risk patients with uncontrolled hypertension on a diuretic and at least one other drug, with effects extending across day and night; these findings are exploratory, and the drug's value depends on the ongoing Phase 3 ZENITH cardiovascular outcomes trial.

Alnylam Pharmaceuticals reported that its drug Amvuttra exceeded $1 billion in global net product revenues in a single quarter for the first time, reaching $1.03 billion in the second quarter of 2026. Total global net product revenues were approximately $1.2 billion, a 74% increase compared to the same period last year. The company revised its full-year 2026 total net product revenue guidance to a range of $4.7 billion to $5.1 billion, citing a normalization of second-line demand growth. Non-GAAP operating income more than tripled to $318 million, while gross margin on product sales declined to 75%, down four percentage points year-over-year due to higher royalties payable to Sanofi. Alnylam also announced a strategic collaboration with B1 for exclusive commercialization and distribution rights for Amvuttra in mainland China and Macau.

Alnylam Pharmaceuticals shares climbed 6.3% after the company presented new clinical data for its Alzheimer’s disease RNAi candidates mivelsiran and ALN-5288 at the Alzheimer’s Association International Conference in London, alongside reporting its first-ever quarter exceeding US$1.00 billion in product revenue. The data included long-term safety findings and robust cerebrospinal fluid biomarker reductions in early-onset Alzheimer’s disease. Alnylam also completed enrollment in the cAPPricorn-1 study in cerebral amyloid angiopathy and initiated the APPlauDS trial in Down syndrome-associated Alzheimer’s disease, highlighting an expanding neuroscience portfolio. The billion-dollar revenue quarter demonstrates sufficient cash flow to finance ambitious neuroscience programs, potentially reducing reliance on the TTR franchise over time. Analysts note that the most bullish projections already assume about US$11.9 billion of revenue and US$3.6 billion of earnings by 2029, and this early Alzheimer’s data could further shift expectations.

Alnylam Pharmaceuticals is set to report second-quarter 2026 results on July 30, with investors watching for continued commercial momentum in its TTR and rare disease franchises. In the first quarter of 2026, total revenue surged 96% to $1.17 billion, driven by a 153% jump in total TTR net product revenues to $910.41 million, led by AMVUTTRA which soared 187% to $889.93 million. Rare disease product revenues also grew, with GIVLAARI up 11% to $74.39 million and OXLUMO up 22% to $51.32 million. The company reiterated full-year 2026 guidance for total TTR net product revenues between $4.40 billion and $4.70 billion, rare net product revenues between $500 million and $600 million, and total net product revenues between $4.90 billion and $5.30 billion. Key pipeline updates include expected completion of enrollment in the cAPPricorn-1 Phase 2 trial of Mivelsiran in the first half of 2026, and multiple data readouts in the second half across programs in Huntington's disease, obesity, and hereditary hemorrhagic telangiectasia.

Alnylam Pharmaceuticals announced the initiation of a global Phase 2 study of its investigational RNAi therapeutic mivelsiran in people with Down syndrome–associated Alzheimer's disease at the Alzheimer's Association International Conference 2026. The APPlauDS study will recruit participants with early-stage Alzheimer's across approximately 30 sites, marking the first clinical trial to evaluate an RNAi approach to reduce APP overexpression caused by trisomy 21. Alnylam also reported updated Phase 1 data in early-onset Alzheimer's disease showing no increased risk of amyloid-related imaging abnormalities and robust reductions in cerebrospinal fluid biomarkers, with mean maximum decreases of 89.9% for sAPPβ and 70.2% for Aβ42 in the highest dose group. The company completed enrollment in the Phase 2 cAPPricorn-1 study of mivelsiran in cerebral amyloid angiopathy, with initial results expected in 2028. Additionally, Alnylam presented preclinical data and the design of an ongoing Phase 1 trial for ALN‑5288, a tau-targeting RNAi therapeutic being developed in collaboration with Regeneron Pharmaceuticals.

Alnylam Pharmaceuticals has drawn fresh attention after shares moved sharply higher, helped by the late-stage failure of a competing ATTR cardiomyopathy therapy from AstraZeneca and Ionis Pharmaceuticals, as well as recent collaboration updates. The most popular narrative assigns a fair value of $434.72, implying the stock is undervalued relative to its last close of $298.76, driven by rapid uptake of AMVUTTRA for ATTR-CM and international expansion. However, the stock trades at a P/E of 74.1x, more than double the peer average of 30.1x and a fair ratio of 34.7x, suggesting investors are already paying a high price for expected growth. Risks include heavier R&D and SG&A spending or pricing pressure on AMVUTTRA that could undercut the bullish narrative.

CNBC's Jim Cramer declared biotech the hottest group in the market, citing a 51% return for the iShares Biotechnology ETF over the past year and a surge in dealmaking following a leadership change at the FDA. Cramer noted that the prior administration nearly blocked an Amgen acquisition, but with new FDA leadership, his sources expect deals to flood the market. Eli Lilly, a $1.16 trillion pharma giant, has already announced four acquisitions in the first quarter of 2026, including Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, and Ajax Therapeutics, fueled by strong sales of Mounjaro and Zepbound. Cramer also highlighted Alnylam Pharmaceuticals as a prime takeover target, with its stock down 21% year-to-date despite 187% revenue growth and a surging TTR drug franchise. He advised investors to be long biotech, a call he has not made in ages.

AstraZeneca shares fell nearly 8% in pre-market trading after the company announced that a phase III study of Wainua failed to meet its primary endpoint in patients with transthyretin-mediated amyloid cardiomyopathy. The CARDIO-TTRansform study did not show a statistically significant benefit for Wainua added to standard of care compared to placebo on the composite outcome of cardiovascular mortality and recurrent cardiovascular clinical events. Ionis Pharmaceuticals, which co-develops the drug, saw its stock slump 19%. Wainua is already approved for polyneuropathy of hereditary transthyretin-mediated amyloidosis, and success in the larger ATTR-CM market had been expected to significantly expand its commercial opportunity. Following the setback, shares of rivals Alnylam Pharmaceuticals and BridgeBio Pharma rose about 18% and 11%, respectively, as their ATTR-CM therapies Amvuttra and Attruby are already on the market.

Alnylam Pharmaceuticals reported $1.04 billion in net product revenues in the first quarter of 2026, a 121% year-over-year increase, driven by its four marketed drugs. Its newest drug, Amvuttra, generated $889.9 million in global sales, up 187% year-over-year, but faces competition in the ATTR-CM market from Pfizer's Vyndaqel family, which brought in $1.6 billion, and BridgeBio's Attruby, with $180.6 million in sales. Alnylam is advancing a broad pipeline to sustain long-term growth, including cemdisiran, for which Regeneron submitted a U.S. regulatory filing in April 2026 after positive phase III results in generalized myasthenia gravis, and zilebesiran, which has entered a global phase III cardiovascular outcomes study with Roche. The company is also developing mivelsiran for early-onset Alzheimer's disease and cerebral amyloid angiopathy, and nucresiran for ATTR amyloidosis, with phase III studies underway. Despite the pipeline progress, Alnylam's stock has fallen 21.4% year-to-date, and it carries a Zacks Rank #4 (Sell), with 2026 earnings estimates declining to $9.05 per share.

Brown Advisory's Large-Cap Growth Strategy exited its position in Veeva Systems during the first quarter of 2026, citing increasing uncertainty around competitive dynamics, particularly in CRM following Salesforce's push into the life sciences vertical, and the evolving role of vertical software in an AI landscape. The strategy noted these factors weighed on near-term visibility, and it reinvested the proceeds into Alnylam Pharmaceuticals. Veeva Systems closed at $192.74 per share on July 2, 2026, with a market capitalization of $31.31 billion, and its shares gained 32.20% over the past 52 weeks. The Brown Advisory Large-Cap Growth Strategy modestly trailed the Russell 1000 Growth Index in the first quarter, with Information Technology and Health Care as the largest detractors, while Industrials and Consumer Discretionary contributed positively.

Brown Advisory's Large-Cap Growth Strategy initiated a position in Alnylam Pharmaceuticals during the first quarter of 2026, citing an attractive entry point after a period of share price weakness. The firm noted Alnylam's demonstrated ability to develop and commercialize novel RNA interference therapeutics, supported by a growing portfolio and durable revenue base. Alnylam reported combined net product revenues of $1.036 billion in Q1 2026, up 121% year-over-year. The stock closed at $312.78 per share on July 2, 2026, with a market capitalization of $41.76 billion. Brown Advisory believes the company's differentiated platform and pipeline position it for sustained long-term growth.

Komodo Health expanded its strategic partnership with Alnylam Pharmaceuticals on June 25, building on Alnylam's adoption of Komodo's Healthcare Map and Marmot analytics AI platform in August 2025. Alnylam Chief Commercial Officer Tolga Tanguler said the expanded capabilities will help the firm turn insights into action, speed up decision-making, scale operations, and support sustainable growth while maintaining its patient focus. Earlier, on June 3, Alnylam announced a separate strategic AI collaboration with Inceptive Nucleics valued at up to $2 billion, including $30 million in upfront consideration through cash and an equity investment, combining Alnylam's RNAi platform and proprietary data with Inceptive's AI foundation models to accelerate RNAi therapeutic discovery.

Komodo Health announced an expanded strategic partnership with Alnylam Pharmaceuticals to scale its analytics AI platform, Marmot, across key enterprise functions at Alnylam. Alnylam, an early adopter of Marmot since August 2025, initially focused on building custom AI agents for its commercial business function. The expanded agreement will deploy Marmot across Alnylam's customer-facing organization and more broadly across the enterprise, creating a unified foundation for data-driven decision-making. Komodo also unveiled new Marmot capabilities designed to move organizations beyond AI experimentation and into enterprise-wide intelligence, including features that make healthcare data accessible to all users while ensuring reproducibility and scientific rigor.

GENESIS Pharma expanded its commercial partnership with Alnylam Pharmaceuticals to include Denmark, Finland, Norway, and Sweden. The extension builds on a collaboration that began in Southeast Europe in 2019 and adds marketing rights for RNAi therapies targeting cardiomyopathy and rare genetic diseases. The agreement now covers 17 markets, including Greece, Romania, and other Southeast European countries, aiming to improve access in areas with unmet medical needs.

Alnylam Pharmaceuticals and Inceptive Nucleics have announced a collaboration valued at up to $2 billion to accelerate the discovery of RNAi therapeutics. Under the agreement, Inceptive will receive $30 million in upfront consideration consisting of cash and equity, with the potential for further payments contingent upon reaching preclinical, regulatory, and commercial milestones. The partnership combines Alnylam's extensive RNAi platform and two decades of proprietary data with Inceptive's foundation models and AI expertise, aiming to unlock innovative oligonucleotide designs and improve experimental productivity. By integrating Inceptive's AI capabilities, led by Transformer architecture co-inventor Jakob Uszkoreit, Alnylam intends to shorten discovery timelines and identify top-performing therapeutic candidates more efficiently, supporting its Alnylam 2030 pipeline expansion strategy.

U.S. and European regulators have accepted marketing applications for cemdisiran, an experimental myasthenia gravis therapy from Regeneron and Alnylam Pharmaceuticals. The FDA granted priority review with a target action date in November, while the European Medicines Agency accepted a marketing authorization application with final European Commission approval expected in the second half of 2027. The submissions seek approval for the injectable to treat adults with generalized myasthenia gravis who are positive for anti-acetylcholine receptor antibodies, supported by the Phase 3 NIMBLE trial. A regulatory filing in Japan is expected in early 2027.

Alnylam Pharmaceuticals' lead drug Amvuttra generated $889.9 million in global sales in the first quarter of 2026, accounting for 76% of the company's total revenues. The figure represents 187% year-over-year growth, driven by strong uptake in ATTR amyloidosis with cardiomyopathy patients in the United States and switches from Onpattro. Alnylam's rare disease portfolio, consisting of Givlaari and Oxlumo, contributed $125.7 million in net product revenues, a 15% increase from the prior year, as the company seeks to reduce its reliance on Amvuttra. The pipeline includes late-stage assets such as zilebesiran in partnership with Roche for hypertension and nucresiran in phase III for ATTR amyloidosis, while Amvuttra faces growing competition from Pfizer's Vyndaqel family, which posted $1.6 billion in global revenues, and BridgeBio's Attruby, which reached $180.6 million in sales. Alnylam shares have fallen 30.1% year-to-date, and the stock trades at a price-to-sales ratio of 8.97, below its five-year mean of 18.24.